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Background: Whether the 7th edition of American Joint Committee on Cancer (AJCC) TNM staging system (AJCC-7) is
a successful revision remains debatable. We aimed to compare the predictive capacity of the AJCC-7 for colorectal
cancer with the 6th edition of the AJCC TNM staging system (AJCC-6).
Methods: The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) dataset consisting of
158,483 records was used in this study. We evaluated the predictive capacity of the two editions of the staging
system using Harrell’s C index and Bayesian Information Criterion (BIC).
Results: There was a significant prognostic difference between patients at stage IIB and IIC (P < 0.001). Stage III
patients with similar prognoses were adequately sub-grouped in the same stage according to AJCC-7. The Harrell’s
C index revealed a value of 0.7692 for AJCC-7, which was significantly better than 0.7663 for AJCC-6 (P < 0.001). BIC
analysis provided consistent results (P < 0.001).
Conclusions: This study demonstrates that AJCC-7 is superior to the AJCC-6 staging system in predictive capacity.
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Colorectal cancer is one of the most common malignan-
cies worldwide [1]. Accurate prognostic prediction of
patients with colorectal cancer is essential for improved
treatment selection. The cancer stage is the strongest
predictor of survival for patients with colorectal cancer.
Accurate staging enables physicians to stratify patients
in terms of expected predicted survival in order to help
select the most effective treatments, determine progno-
ses, and evaluate cancer control measures [2]. The
International American Joint Committee on Cancer
(AJCC) TNM staging system is currently regarded as
the strongest prognostic parameter for patients with
colorectal cancer [3]. Over the past several decades, the
TNM staging system has continued to develop, and in* Correspondence: josieon826@yahoo.com.cn
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reproduction in any medium, provided the or2010 the 7th revision of TNM staging [4] (AJCC-7) was
published by the AJCC and replaced the 6th edition [5]
(AJCC-6) issued in 2002. The basic staging principals
remained unchanged; however, some subtle changes
were made. The major changes in the AJCC-7 are as
follows:
1) T4 lesions are subdivided as T4a (Tumor penetrates
the surface of the visceral peritoneum) or T4b.
(Tumor directly invades or is histologically adherent
to other organs or structures);
2) T1-2 lesions that lack regional lymph node
metastasis but exhibit tumor deposit(s) are classified
in addition as N1c;
3) N1 tumors are subdivided as N1a (metastasis in 1
regional node) and N1b (metastasis in 2–3 nodes),
and N2 tumors are subdivided as N2a (metastasis in
4–6 nodes) and N2b (metastasis in 7 or more nodes);. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(T4aN0), and IIC (T4bN0);
5) T4bN1 is reclassified from IIIB to IIIC;
6) T1N2a is reclassified as IIIA, and T1N2b, T2N2a-b,
and T3N2a are all reclassified as IIIB;
7) M1 tumors are subdivided into M1a (single
metastatic site) and M1b (multiple metastatic
sites).
A diagram of the major differences between AJCC-7
and AJCC-6 was presented in Figure 1.
After the publication of AJCC-7, its prognostic validity
was discussed worldwide. Whether AJCC-7 is a success-
ful revision remains debatable. Some previous studies
have validated supported the revisions introduced [6-9].
However, reports by Mori [10] and Nagtegaal [11,12]
have raised objections to the revisions; in particular,
Nitsche [13] suggested that AJCC-7 did not provide
greater accuracy in predicting colorectal cancer patients’
prognosis compared with AJCC-6.
This study aimed to analyze the prognostic validity of
AJCC-7 for colorectal cancer in comparison to AJCC-6;
we applied the National Cancer Institute’s Surveillance,
Epidemiology, and End Results (SEER) dataset for
statistical analysis.Figure 1 Diagram of the major differences between the 6th
and the 7th editions of the American Joint Committee on
Cancer (AJCC-6 and AJCC-7, respectively) staging system for
colorectal cancer.Methods
Data from the SEER program
The dataset we used is the National Cancer Institute’s
SEER dataset, 1973–2008. SEER collects data on cancer
cases from various locations and sources throughout the
United States and the program is regarded as a model
population-based tumor registry. This national program
includes 17 regional registries that cover approximately
28% of the US population. The number of records in-
cluded in the SEER dataset reaches 6,551,087, including























*: Mean ± SD.
∫: The pT categ.ory of patients with distant metastasis is unavailable.
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Patients diagnosed from 1991 through 2003 were selected
for analysis. The primary study endpoint was cancer-
specific survival.
We selected tumors according to the primary site as
follows: cecum, ascending colon, hepatic flexure, trans-
verse colon, splenic flexure, descending colon, sigmoid
colon, overlapping lesion of colon, colon NOS (not other-
wise specified), rectosigmoid junction, and rectum NOS.
We further restricted the tumors included by specific
histologic type, as defined by the following individual
International Classification of Diseases for Oncology, third
edition (ICD-O-3), codes: 8000–8152, 8154–8231, 8243–
8245, 8250–8576, 8940–8950, 8980–8981 in accordance
with AJCC-7 [4]. Patients were excluded from this
study if they exhibited: 1) prior non-colorectal cancer;
2) in situ tumors; 3) incomplete pathological data en-
tries; or 4) died during the immediate postoperative
period (within 30 days).
After using these inclusion and exclusion strategies, a
dataset consisting of 158,483 records was constructed
and the following data were recorded: age, gender, race,
primary tumor site, number of lymph nodes retrieved,
AJCC-6 TNM stage, and AJCC-7 TNM stage. Both TNM
stages were determined by SEER’s “extent of disease” (for
T category and M category) and “regional nodes positive”
(for N category) coding schemes. The N1c category was
not included because the information of tumor deposits
was not supported by the SEER program. We considered
stage IV in its entirety because the number of metastatic
organ/site was unknown in the SEER program. The clini-
copathologic features of the colorectal patients are listed
in Table 1.Ethics statement
This study was in compliance with the Helsinki Declar-
ation. We have got permission to access the research data
file in SEER program and the reference number was 10188-
Nov2011. The study was also approved by the ResearchFigure 2 Survival curves of patients in two datasets. Stage-dependent
(b), sixth edition of the TNM classification.Ethics Committee of China Medical University, China and
the reference number was [2012]96.
Statistical analysis
Continuous data are presented as mean ± standard devi-
ation (SD). Cancer-specific survival was analyzed using
Kaplan-Meier survival curves, and comparisons were
made using the log-rank test.
We evaluated the predictive capacity of the different
categories by investigating measures of discrimination.
Discrimination refers to the ability to distinguish be-
tween high-risk and low-risk patients, and we quantified
discrimination using the Harrell’s C index [14,15] and
the Bayesian Information Criterion (BIC) [16]. A model
with perfect predictive capacity (sensitivity and specifi-
city of 100%) would have a Harrell’s c-index of 1.00; a
category that exhibited a higher Harrell’s C index was
considered to exhibit a more accurate predictive capacity.
BIC was used to assess the overall prognostic performance
of different classification systems via bootstrap-resampling
analysis. A smaller BIC value indicates a more desirable
model for predicting outcome.
All statistical analyses and graphics were performed
using the PASW Statistics 18.0 software (SPSS, Inc.,
Somers, NY, USA) and STATA MP ver. 10 (StataCorp LP,
College Station, TX) statistical software. For all analyses,
P < 0.05 was considered to indicate a significant result.
Results
Survival outcomes by two editions of staging system
Comparisons of survival curves between patients in dif-
ferent TNM stage according to the AJCC-6 and AJCC-7
were presented in Figure 2. As shown, significant prognos-
tic differences could always be observed in both AJCC-6
and AJCC-7 (p < 0.001).
Revisions appeared in the AJCC-7 concerning stage II,
stage III, and stage IV patients. Regarding stage II, we
found significant differences in prognosis between patients
categorized as AJCC-7 stage IIB and IIC (P < 0.001)
(Figure 3). Regarding stage III, the patients with similarsurvival according to allocation of the patients to (a), seventh, or
Figure 3 Differences in cause-specific survival between patients
in stage IIB and stage IIC of the seventh edition of the TNM
staging system.
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there were significant differences in survival among pa-
tients in stage IIIA, IIIB, and IIIC (P < 0.001; Figure 4a).
However, based on AJCC-6, some patients were not
sub-grouped into a reasonable stage: 1) no significant
difference in survival was found between patients with
T1N2a in stage IIIC and patients with T1-2N1b in stage
IIIA (P = 0.874); 2) there was no significant difference
between patients with T2N2a in stage IIIC and patients
with T3N1a in stage IIIB (P = 0.785); 3) the prognosis of
patients with T4aN1b in stage IIIB was similar to patients
with T1-2N2b in stage IIIC (P = 0.595) and patients with
T3N2a in stage IIIC (P = 0.404; Figure 4b). These results
support the revisions found in AJCC-7.
After the comparisons of prognoses among patients
from the SEER dataset in different AJCC-6 stages strati-
fied by AJCC-7, and among those in different AJCC-7
stages stratified by AJCC-6, we found that there were
significant differences in survival for the patients in
AJCC-6 stage IIB (P < 0.001), IIIB (P < 0.001), and IIICFigure 4 Survival curves of patients in stage III. Survival curves of patie
according to (a), seventh, or (b), sixth edition of the TNM staging system.(P < 0.001) when stratified by AJCC-7. When stratified
by AJCC-6, significant differences in survival were not
observed for AJCC-7 stage IIIA (P = 0.517) and IIIC
(P = 0.283) patients; however, differences were observed
for AJCC-7 stage IIIB (P < 0.001) patients (Table 2).
Comparison of the prognostic capacity between AJCC-7
and AJCC-6
Statistical assessment of the prognostic performance of
the two editions by the Harrell’s c-index revealed a value
of 0.7692 for AJCC-7, which was significantly better than
0.7663 for AJCC-6 (P < 0.001; Table 3). The prognostic
performances of the two staging systems were also com-
pared using BIC. As shown in Table 3, the prognostic
performance of AJCC-7 was significantly superior to
AJCC-6 (P < 0.001).
Discussion
Accurate staging is necessary to evaluate the prognosis
of patients and is a critical element in determining ap-
propriate treatment based on the experiences and out-
comes of groups of prior patients with a similar stage.
The AJCC TNM system is currently the most clinically
useful staging system. However, unresolved issues in the
latest edition remain and further investigation is
warranted. Whether AJCC-7 exhibits a greater predictive
capacity compared to AJCC-6 remains unclear [10,11,13].
For the first time, we compared the predictive capacity
between AJCC-7 and AJCC-6 using two independent
datasets.
Compared with AJCC-6, stage IIB is subdivided into
IIB (T4aN0) and IIC (T4bN0) in AJCC-7. Lan [9] and
Nitsche [13] proposed that there was not a marked dif-
ference in outcome between the two sub-stages. Kim [8]
also found no significant difference in survival rate be-
tween patients with stage IIB and stage IIC cancer, but
proposed that there was a trend toward a better survival
rate for patients with stage IIB cancer. Based on the
SEER dataset, a report by Gunderson indicated that
there were large differences in the 5-year survival ratents in stage IIIA (yellow lines), IIIB (green lines), IIIC (blue lines)
Table 2 Comparison of 5-year survival rate based on the 6th edition of TNM system according to the 7th edition of
TNM system
The 7th edition (n, 5-YSRb)




IIB 4868(76.3%) 3323(58.8%) <0.001
IIIA 5211(83.1%) N/A
IIIB 25814(66.6%) 2002(36.3%) <0.001
IIIC 108(80.4%) 8009(54.8%) 8686(35.0%) <0.001
IV 21363(10.4%) N/A
P value N/A N/A N/A N/A 0.517 <0.001 0.283 N/A
5-YSRb: 5-year survival rate.
N/Ac: not applicable.
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[6]. In the present study, we found a significant differ-
ence in prognosis between AJCC-7 stage IIB and IIC pa-
tients (P < 0.001, Figure 3). It is valuable to subdivide
patients into IIB and IIC based on whether the tumor
directly invades or is histologically adherent to other
organs or structures.
For stage III patients, those who exhibited a similar
prognosis were adequately sub-grouped into the same
stage according to AJCC-7 (Figure 4a). However, based
on AJCC-6, some patients were not sub-grouped into a
reasonable stage (Figure 4b). Therefore, the results were
more in accordance with AJCC-7.
Based on the SEER dataset, we found that there were
significant differences in survival for AJCC-6 stage IIB,
IIIB, and IIIC patients when stratified by AJCC-7. How-
ever, no significant differences in prognosis were observed
for the AJCC-7 stage IIIA and IIIC patients when stratified
by AJCC-6 (Table 2). Although there was a significant dif-
ference in survival for AJCC-7 stage IIIB when stratified
by AJCC-6, the staging was reasonable because the dif-
ference in survival between the migrated patients and
patients both in stage IIIC of AJCC-6 and AJCC-7 was
even more significant (5-year survival rate: 54.8% vs.
34.0%, p < 0.001). These results indicated that using




The 6th edition TNM stage 0.7663 0.7644-0.7
The 7th edition TNM stage 0.7692 0.7673-0.7
BICa: Bayesian Information Criterion.
CIb: confidence interval.classification and greater power to subgroup patients
with a more homogenous prognosis compared to
AJCC-6.
Two comprehensive statistical methods, Harrell’s C
index and BIC, were used to compare the predictive
capacity of AJCC-7 and AJCC-6. Both of the two tests
revealed that the prognostic performance of AJCC-7 was
significantly better compared to AJCC-6 (Table 3).
Nitsche [13] proposed that AJCC-7 did not provide
greater accuracy in predicting colorectal cancer patient
prognosis compared with AJCC-6 based on a European
single-center collective. However, in their published data
we found that AJCC-7 exhibited a better predictive
capacity according to the results of c-index and BIC, al-
though the differences were not significant. It is possible
that the differences between the results of the two tests
were caused by different sample sizes. Stage migration
occurred in only 8.48% (13442/158483) of patients from
the SEER dataset used in this study and 13.5% (302/2229)
of patients from the study by Nitsche. The total number
of reclassified patients was small. Therefore, only when
the comparison was based on a large dataset such as SEER
the difference between AJCC-6 and AJCC-7 was signifi-
cantly validated. When the comparisons were based on a
relatively small dataset, it was difficult to obtain significant
results, although a tendency that AJCC-7 exhibited acriterion between the 6th and 7th edition TNM staging
dex BICa
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observed.
The classification of tumor deposits varied enormously
in AJCC-7. These changes have been criticized as con-
fusing and as exhibiting low reproducibility in the study
by Nagtegaal [11]; however, they also proposed that
AJCC-7 exhibited greater prognostic value than other
staging systems when all tumor deposits irrespective of
size or contour were included as lymph nodes. In our
previous study [17], we found that the classification of
tumor deposits in AJCC-7 satisfactorily predicted patients’
outcome for those without lymph node metastases. How-
ever, we also found that patients who were categorized as
T3-4N2b with tumor deposits should be reclassified as
stage IV. In the present study, it was not possible to com-
pare the classification of tumor deposits in AJCC-7 with
that in AJCC-6 because the SEER dataset did not identify
the status of tumor deposits. Furthermore, the number of
metastatic organ/site was unknown in the SEER program.
Considering these two points, this study answers only well
defined parts of the question about the comparison of
AJCC-7 with AJCC-6.
Our study does have some limitations. It is a retro-
spective exploratory study. Clinical and pathologic pa-
tient information can be heterogeneous because SEER
collects information from 12 population-based cancer
registries. On the other hand, in the SEER dataset, data
on adjuvant therapy is limited to information on radi-
ation therapy only and the information of chemotherapy
is unavailable.
Conclusions
This study demonstrates that AJCC-7 is superior to the
AJCC-6 staging system in predictive capacity. We recom-
mend that this staging system be considered for clinical
application.
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